Skip to content Skip to footer
Subscribe Now
Top 20 Biopharma 2025
TOP 20

Top 20 Biopharma Companies of 2025 

Shots: Driven by innovation and a steadfast commitment to advancing cutting-edge therapies, the biopharma industry experienced robust growth in 2024, marked by significant revenue milestones With a projected compound annual growth rate (CAGR) of 12.87%, the global biopharma market is expected to reach $1.41 trillion by 2032. In 2024, Pfizer led the industry with total…
April 24, 2025

Read more

Spending on R&D Top 20 2022
TOP 20

Top 20 Companies Spending on R&D in 2022

Shots:R&D (Research and Development) in the biopharma industry lays the foundation stone of innovative drugs. A robust R&D bolstered with new-age technological advances assures long-term sustainability in the future marketWith a global expenditure of $238B in 2022, the figures are anticipated to reach $285B by 2028. In 2022, AbbVie ranked the top among…
August 22, 2023

Read more

Companies Spending on R&D Top 20 2022
TOP 20

Top 20 Companies Spending on R&D in 2022

Shots:R&D (Research and Development) in the biopharma industry lays the foundation stone of innovative drugs. A robust R&D bolstered with new-age technological advances assures long-term sustainability in the future marketWith a global expenditure of $238B in 2022, the figures are anticipated to reach $285B by 2028. In 2022, AbbVie ranked the top among…
August 22, 2023

Read more

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)
INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Shots:With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturingWhile major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…
April 13, 2023

Read more

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value
TOP 20

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Shots:Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnershipTo tackle such scenarios, companies are cautious enough to make backup plans beforehand…
March 22, 2023

Read more